Translational Development Acquisition Corp.

Translational Development Acquisition Corp. (Nasdaq: TDAC) is a blank-check company formed to pursue a merger or acquisition in the life sciences and healthcare sector, where the term "translational development" refers to bridging early-stage research with clinical and commercial application. The company filed a Form 10-Q with the Securities and Exchange Commission on August 14, 2026 (accession no. 0001104659-26-097093), indicating it remains an active public reporting entity. Like other SPACs in the biotech and life sciences space, TDAC was structured to identify a target company capable of advancing novel therapeutics or medical technologies toward broader deployment. For full sponsor details, deal pipeline updates, and filing history on TDAC, sign up for a SpacDesk account at spacdesk.com.